Wegovy is no longer a name that tells you only “weekly injection.” The current prescribing information includes an oral tablet as well as injectable formulations. Both contain semaglutide, but that does not make their instructions interchangeable.
A choice between them involves clinical suitability, the approved use, the day-to-day routine, and cost. This guide is a way to prepare for that discussion, not a recommendation to switch or convert a dose yourself.
One thing to keep with you
A tablet amount is not a milligram-for-milligram substitute for an injection. Ask for a product-specific plan.
Begin with the labeled use
The June 2026 Wegovy label describes different indications for tablets and injections. Some uses overlap, while others depend on the formulation and patient group. For example, the oral weight-management indication concerns adults; pediatric or liver-disease wording should not be carried over from an injection label without checking.
Ask which exact formulation is proposed and why. The semaglutide introduction explains why the ingredient name alone does not settle an indication or establish eligibility.
Checked with: Wegovy: current prescribing information · MedlinePlus: GLP-1 medicines
The routine is different
Wegovy injection is administered weekly, while Wegovy tablets are taken daily under specific fasting and water instructions. Those administration details can affect how the oral product is absorbed. A general article about taking injections without regard to meals should not be applied to a tablet.
Review the actual medication guide with the pharmacist, especially if you take other morning medicines. This article deliberately does not supply a personalized schedule, switching sequence, or dose conversion. A clinician should decide how any change is made.
Checked with: Wegovy: current prescribing information · MedlinePlus: semaglutide information
The safety conversation still matters
A pill avoids a needle, but it does not remove semaglutide’s important warnings and contraindications. The exact product label, medical history, other medications, and any planned procedures still belong in the discussion.
Use our side-effect and safety guide to prepare questions. If the alternative being advertised is a compounded oral or injectable product, it is also a different regulatory category. The compounding guide explains why a shared ingredient is not enough to establish approved-product equivalence.
Checked with: Wegovy: current prescribing information · FDA: concerns about unapproved GLP-1 products
Compare the price at the actual strength
Manufacturer self-pay prices can vary by strength and formulation, and introductory offers can have time and eligibility limits. A starting tablet price and a starting injection price do not necessarily represent the same stage of care or the same ongoing bill.
Our NovoCare review and cost guide record the public terms checked September 23, 2026. Ask what the price would be for the prescribed product and whether a separate care membership or visit fee applies.
Checked with: NovoCare: Wegovy pharmacy offer · Ro: current program pricing
Where we checked the facts
- Wegovy: current prescribing information
June 2026 label includes oral and injectable formulations with product-specific uses and instructions. Do not apply one formulation’s directions to another.
- MedlinePlus: GLP-1 medicines
General patient education about the medicine class, not individual eligibility advice.
- MedlinePlus: semaglutide information
Patient medication information; the actual prescription and current product labeling govern use.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
- NovoCare: Wegovy pharmacy offer
Manufacturer access and pricing terms checked September 23, 2026. Formulation, strength, eligibility and offer period affect cost.
- Ro: current program pricing
Membership and medication are separate charges. $39 introductory membership; $149 ongoing monthly or lower prepaid equivalents, subject to terms.
